2025 France 23-Valent Pneumococcal Vaccine Market Revenue Opportunities Report
Description
The 2025 France 23-Valent Pneumococcal Vaccine Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the 23-valent Pneumococcal Vaccine Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the 23-valent pneumococcal vaccine market in France are Merck & Co., Pfizer Inc., Sanofi S.A., and GlaxoSmithKline (GSK). Merck markets the 23-valent pneumococcal polysaccharide vaccine (Pneumovax 23), which is widely used for active immunization against pneumococcal disease in adults and high-risk groups in France. Pfizer leads with its conjugate vaccines Prevnar 13 and Prevnar 20, dominating the conjugate vaccine segment and holding significant market share in Europe, including France. Sanofi Pasteur, approved to market pneumococcal vaccines like PCV15, contributes to vaccine availability and ongoing R&D. GSK focuses on pediatric and adult immunization with its pneumococcal vaccine Synflorix in this region.
These companies drive the market through continuous product development, regulatory approvals, and strategic collaborations. Merck recently announced positive Phase 3 results for its investigational 21-valent conjugate vaccine, designed for adults with added serotypes not covered by existing vaccines, potentially expanding its market impact in France and Europe. Sanofi and Pfizer maintain collaborations and innovation pipelines to meet diverse population needs. The France pneumococcal vaccine market was valued at about USD 128.6 million in 2023, projected to grow rapidly, with these companies engaging actively in clinical trials, commercial launches, and expanding distribution networks to capture this growth.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the 23-valent Pneumococcal Vaccine Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the 23-valent pneumococcal vaccine market in France are Merck & Co., Pfizer Inc., Sanofi S.A., and GlaxoSmithKline (GSK). Merck markets the 23-valent pneumococcal polysaccharide vaccine (Pneumovax 23), which is widely used for active immunization against pneumococcal disease in adults and high-risk groups in France. Pfizer leads with its conjugate vaccines Prevnar 13 and Prevnar 20, dominating the conjugate vaccine segment and holding significant market share in Europe, including France. Sanofi Pasteur, approved to market pneumococcal vaccines like PCV15, contributes to vaccine availability and ongoing R&D. GSK focuses on pediatric and adult immunization with its pneumococcal vaccine Synflorix in this region.
These companies drive the market through continuous product development, regulatory approvals, and strategic collaborations. Merck recently announced positive Phase 3 results for its investigational 21-valent conjugate vaccine, designed for adults with added serotypes not covered by existing vaccines, potentially expanding its market impact in France and Europe. Sanofi and Pfizer maintain collaborations and innovation pipelines to meet diverse population needs. The France pneumococcal vaccine market was valued at about USD 128.6 million in 2023, projected to grow rapidly, with these companies engaging actively in clinical trials, commercial launches, and expanding distribution networks to capture this growth.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
